Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 7/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | FABP6 | P51161 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30812538 | 1.00 | MAP3K14 (0.65) | MAP3K14ADRA2AKDM4CNR3C2HTR1A | |
| SCHEMBL22143947 | 1.00 | MAP3K14 (0.65) | MAP3K14ADRA2AKDM4CNR3C2HTR1A | |
| SCHEMBL1477701 | 0.86 | MAP3K14 (0.51) | MAP3K14ADRA2AHTR1ATRPV1FABP6 | |
| SCHEMBL22143742 | 0.86 | MAP3K14 (0.51) | MAP3K14ADRA2AHTR1ATRPV1FABP6 | |
| SCHEMBL12749284 | 0.86 | MAP3K14 (0.51) | MAP3K14ADRA2AHTR1ATRPV1FABP6 | |
| SCHEMBL1111009 | 0.80 | MAP3K14 (0.67) | MAP3K14 | |
| SCHEMBL14183091 | 0.80 | MAP3K14 (0.67) | MAP3K14 | |
| SCHEMBL2953873 | 0.79 | HTR6 (0.50) | MAP3K14 | |
| SCHEMBL24593571 | 0.79 | ADRA2A (0.50) | MAP3K14ADRA2AKDM4CHTR1ATRPV1 | |
| SCHEMBL3555891 | 0.79 | ADRA2A (0.50) | MAP3K14ADRA2AKDM4CHTR1ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-7718809-B2 | Chromane substituted benzimidazole derivatives as acid pump antagonists | RAQUALIA PHARMA INC. (JP) | 2010-05-18 | — | — | US | disclosed |
| EP-1893197-B1 | CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008151927-A2 | 6-N-SUBSTITUTED BENZ IMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS | NYCOMED GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080214519-A1 | Chromane Substituted Benzimidazole Derivatives as Acid Pump Antagonists | RAQUALIA PHARMA INC. (JP) | 2008-09-04 | — | — | US | disclosed |
| EP-1893197-A1 | CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006134460-A1 | CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
| US-5521147-A | HERBICIDES | FMC CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214519-A1 | Chromane Substituted Benzimidazole Derivatives as Acid Pump Antagonists | HRH2, HRH4, HRH1 | MAP3K14 2415/4885ADRA2A 310/4885KDM4C 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.